DOCSLIB.ORG

University of Groningen Adverse Reactions to Cosmetics Groot

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
University of Groningen Adverse Reactions to Cosmetics Groot University of Groningen Adverse Reactions to Cosmetics Groot, Anton Cornelis de IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1988 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Groot, A. C. D. (1988). Adverse Reactions to Cosmetics. [s.n.]. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 07-10-2021 ADVERSE REACTIONS TO COSMETICS Stellingen 1. De hoeveelheid vrije formaldehyde in cosmetische producten die geconserveerd worden met DMDM hydantoin is voldoende om bij sommige individuen met contactallergie voor formaldehyde dermatitis te induceren (A.C. de Groot et al. Contact Dermatitis 1988; 18: 197) 2. Pre-marketing onderzoek naar irritatieve effecten van cosmetische producten dient bij voorkeur bij atopici te warden uitgevoerd. 3. Om onnodige angst bij de gebruiker te voorkomen, dient de informatie over mogelijke bijwerkingen, vermeld op de bijsluiter van geneesmid­ delen, meer genuanceerd te warden weergegeven. 4. Het idee, dat voor het ontstaan van "allergie" nieuwe contactstoffen geintroduceerd dienen te zijn, blijkt onder leken, maar oak onder huisartsen, wijdverbreid. 5. Het is dringend noodzakelijk, dat de vermelding van alle bestanddelen van cosmetica op de verpakking in EEG verband wettelijk verplicht wordt gesteld. 6. Lokaal toegepast minoxidil heeftbij mannelijke patienten met alopecia androgenetica zelden een cosmetisch acceptabele mate van nieuwe haargroei tot gevolg. 7. De consequente afwijzing door een aantal "bewuste" moeders van corticosteroiden-bevattende zalven is nadelig voor hun kinderen met ernstig atopisch eczeem. 8. Het College Ter Beoordeling van Geneesmiddelen (Rijswijk) dient over meer wettelijke bevoegdheden te beschikken om registratie van nieuwe geneesmiddelen te weigeren. 9. Methyl(chloor)isothiazolinon (Kathan CG) 100 ppm in water dient aan de Europese standaardreeks van veel voorkomende contactaller­ genen te warden toegevoegd (A.C. de Groot en J.D. Bos. Brit J Derm 1987; 116: 289). 10. Opschriften op cosmetica als "zuiver plantaardig", "zonder chemische toevoegingen", "gaat rimpelvorming tegen", duiden erop dat het beleid van de Nederlandse overheid ten aanzien van Artikel 6.2 van de EEG cosmetica wetgeving (Cosmetic Directive 76/768/EEC) niet het ge­ wenste effect heeft. 11. De diagnose "compound allergie" verbergt vaak inadequate diagno­ stiek. 12. Gegevens over bijwerkingen van cosmetica, aan de Keuringsdienst van Waren gemeld door medici en consumenten, zijn epidemiologisch gezien van geen waarde. 13. Nu blijkt dat irritatie de meest voorkomende bijwerking van cosmetica is, kan op korte termijn de introduktie van "hypo-irriterende" pro­ dukten tegemoet gezien worden. 14. Dermatologische studies over bijwerkingen van cosmetica dienen door de cosmetische industrie gebruikt te worden ter optimalisering van de produkt-veiligheid, en niet opgevat te worden als een aanval op hun branche. 15. Toepassen van parabenen in cosmetica is relatief veilig. 16. De aanwezigheid van formaldehyde in nagelverharders die tolueen­ sulfonamide/formaldehyde hars bevatten, verhoogt mogelijk de kans op sensibilisatie voor de hars (FS de Wit et al. Contact Dermatitis 1988; 18: 280). 17. Het "moment" van telefonistes doet vermoeden dat zij een andere tijdsrekening hanteren dan gebruikelijk is. 18. Voor verdergaande bezuinigingen in de Gezondheidszorg ontbreekt een breed maatschappelijk draagvlak. 19. Partnerruil komt in bridgekringen niet zelden voor. RIJKSUNIVERSITEIT GRONINGEN ADVERSE REACTIONS TO COSMETICS PROEFSCHRIFf ter verkrijging van het doctoraat in de GENEESKUNDE aan de Rijksuniversiteit Groningen op gezag van de Rector Magnificus Dr. L.J. Engels in het openbaar te verdedigen op woensdag 21 december 1988 des namiddags te 4.00 uur door ANTON CORNELIS DE GROOT geboren te Deventer Promotores: Prof. Dr. J.P. Nater Prof. Dr. E. Bleumink Referent: Dr. P.J. Coenraads PROMOTIECOMMISSIE: Prof. Dr. M.N.G. Dukes Prof. Dr. 1-1. Wesseling Prof. Dr. E. Young (Thesis, State University of Groningen, The Netherlands, 1988) Aan mijn ouders Aan Janny, Elleke en Suzan Dankwoord I Acknowledgement Velen hebben bijgedragen aan de totstandkoming van dit proefschrift. Mijn bijzondere erkentelijkheid gaat uit naar de volgende personen: - Prof. Dr. Johan P. Nater, zonder wiens niet-aflatende aandringen ("Je moet toch echt promoveren, Ton") dit proefschrift nooit tot stand zou zijn gekomen. Het is een voorrecht en een groot genoegen bij hem te kunnen promoveren. - Prof. Dr. Erik Bleumink, die het totstandkomen van dit proefschrift begeleidde, en die de overzichtelijkheid ervan sterk bevorderd heeft. - Dr. Andrew Herxheimer, Ph.D., who was the first to interest me in scientific work. - Dr. Pieter Jan Coenraads, die het totstandkomen van dit proefschrift begeleidde, en die vele constructieve ideeen aandroeg. - Dr. J. Willem Weyland, Ph.D. en Dhr. Gerrit Rundervoort (Keurings­ dienst van Waren Enschede), die een zeer belangrijk aandeel hadden in de uitvoering van diverse projekten. Van hen heb ik veel geleerd op bet gebied van cosmetica. - De (voormalige) !eden van de Commissie Contactdermatosen, die een belangrijke bijdrage leverden in een aantal studies. Met name gaat mijn dank uit naar de collegae: Dr. Derk P. Bruynzeel, Dr. Jan D. Bos, Dr. Harrie L.M. van der Meeren, Prof. Dr. Th. van Joost, en Dr. Berend A. Jagtman. Ik ben hen zeer erkentelijk dat zij mij toestonden hun gegevens voor dit proefschrift te gebruiken. - Prof. Dr. R. van der Lende, die bet mogelijk maakte epidemiologiscb onderzoek te doen in "zijn" Vlagtwedde-populatie. - Enny G.A. Beverdam en Christien Tjong Ayong, die veel werk verricht hebben bij het onderzoek in Vlagtwedde, en bij de studie onder clienten van schoonheidsspecialistes. - De schoonheidsspecialistes, die hun clienten interviewden en hen aan­ spoorden aan het onderzoek medewerking te verlenen. - Drs. Jean M.H. Conemans en Dbr. Clement G.J. Barella, die veel analytisch werk verricht hebben. - Mr. Gordon L. Lackie, who reviewed the English. - De Stichting Carolus-Liduina Ziekenhuis en Verpleeghuis, die een dee! van de drukkosten heeft gedragen. VI Table of contents Aims of the Studies IX Chapter 1 Introduction l. 1 Cosmetics: what they are and what they do 2 1.2 Cosmetics: the extent of their usage 3 1.3 The ingredients of cosmetics 6 1.4 Adverse reactions to cosmetics and toiletries 17 1.5 Legislation in the European Economic Community 27 1.6 References 30 Chapter 2 Adverse reactions to cosmetics: Frequency, nature, and products involved 2.1 Introduction 36 2.2 Literature survey 37 2.3 Adverse effects of cosmetics and toiletries: A retrospective study in the general population 41 2.4 The role of contact allergy in the spectrum of adverse effects caused by cosmetics and toiletries 47 2.5 Routine testing with preservatives and fragrance materials in patients with suspected cosmetic-related allergic contact der- matitis 54 2.6 Routine testing with preservatives in patients with suspected allergic contact dermatitis 60 2. 7 Conclusions 65 2.8 References 66 Chapter 3 The Allergens in cosmetics 3.1 Introduction 72 3.2 Literature survey 72 3.3 The allergens in cosmetics: a retrospective study 100 vii 3.4 The allergens in cosmetics: a prospective study 105 3.5 Rare cosmetic allergens: a summary of published cases 113 3.6 Conclusions 122 3. 7 References 124 Chapter 4 Kathon CG 4.1 Introduction 144 4.2 What is "Kathan" 144 4.3 Toxicological studies 146 4.4 Exposure of the population to Kathan CG 151 4.5 Concentration and vehicle for patch testing 153 4.6 Clinical studies 154 4.7 Profile of the patients sensitised to Kath on CG 158 4.8 Use tests in patients allergic to Kathan CG 159 4.9 Relevance of positive patch test reactions to Kathan CG 160 4.10 The sensitiser in Kathan CG 162 4.11 Conclusions 163 4.12 References 164 Chapter 5 Oleamidopropyl dimethylamine 5.1 Introduction 170 5.2 Product description 170 5.3 Clinical aspects of contact allergy to oleamidopropyl dimethylamine 171 5.4 Frequency of sensitisation 173 5.5 Cross-reaction pattern 174 5.6 Conclusions 181 5.7 References 181 Chapter 6 Summary, Conclusions, Recommendations 183 Appendices 1 Usage pattern of cosmetics and toiletries 189 2 Results of patch testing with cosmetic ingredients 193 3 The European standard series 203 Index of chemicals 205 Vlll Aims of the studies Cosmetics and toiletry products are used by everyone for the daily care and hygiene of the body, to enhance attractiveness, to obtain
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Commission Decision of 8 February 2010 Concerning The
    L 36/36 EN Official Journal of the European Union 9.2.2010 COMMISSION DECISION of 8 February 2010 concerning the non-inclusion of certain substances in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (notified under document C(2010) 751) (Text with EEA relevance) (2010/72/EU) THE EUROPEAN COMMISSION, concerned should therefore not be included in Annex I, IA or IB to Directive 98/8/EC. Having regard to the Treaty on the Functioning of the European Union, (6) In the interest of legal certainty, biocidal products Having regard to Directive 98/8/EC of the European Parliament containing active substances for the product-types and of the Council of 16 February 1998 concerning the placing indicated in the Annex to this Decision should no of biocidal products on the market ( 1), and in particular the longer be placed on the market, with effect from a second subparagraph of Article 16(2) thereof, specific date. Whereas: (7) The measures provided for in this Decision are in accordance with the opinion of the Standing (1) Commission Regulation (EC) No 1451/2007 of Committee on Biocidal Products, 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive HAS ADOPTED THIS DECISION: 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the Article 1 market ( 2) establishes a list of active substances to be assessed, with a view to their possible inclusion in The substances indicated in the Annex to this Decision shall not Annex I, IA or IB to Directive 98/8/EC.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • Ulllted States Patent [19] [11] Patent Number: 5,120,325 Dow, Jr
    _ US005120325A Ulllted States Patent [19] [11] Patent Number: 5,120,325 Dow, Jr. [45] Date of Patent: Jun. 9, 1992 [54] COLOR-MATCHED STERILE ADHESIVE 4,561,435 12/1985 McKnight et al. ............... .. 604/304 BANDAGES CONTAINING MELANINLIKE 4,699,792 10/1987 Nick et a1. 1 . .. 604/307 PIGMENT COMPOSITION 4.710,191 12/1987 Kwiatek et a1. 604/304 4,728,323 3/1988 Matson .............. .. ‘604/304 [75] Inventor: James E. Dow, Jr., Hackensack, NJ. 4,745,916 5/1988 Seber ..... .. 128/155 , 4,895,727 l/l990 Allen 424/642 [731 Asslgnw Fleshtones Products (30-11119, 4,990,144 2/1991 Blott .................................. .. 604/304 Hackensack, NJ. Primary Examiner-David Isabella 1211 Appl- N04 713,827 Assistant Examiner—Dinh X. Nguyen [22] Filed: Jam 12, 1991 Attorney, Agent, or Firm-Carl W1 Battle [51] 11.1.0.5 ..................... .. A61F 13/00; A61F 13/02 [57] ABSTRACT [52] U.S. Cl. .................................. .. 604/304; 604/307; A sterile bandage suitable for external application to a 602/41; 602/42; 602/58 wound or injury of the human skin comprising a back [58] Field of Search .............. .. 604/304, 307; 128/156; ing layer, a non-toxic pigmented composition coated 424/447, 448 onto or embedded into the top side of said backing [56] References Cited layer, wherein said pigmented composition comprises one or more pigments having a melanin likeness in ap U.S. PATENT DOCUMENTS pearance so as to substantially match the appearance of said human skin. 3,987,202 10/1976 Okun ................................... .. 424/70 4,161,176 7/1979 Harris, U et a1.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Quantitative Assessment of Antimicrobial Activity of PLGA Films Loaded with 4-Hexylresorcinol
    Journal of Functional Biomaterials Article Quantitative Assessment of Antimicrobial Activity of PLGA Films Loaded with 4-Hexylresorcinol Michael Kemme * and Regina Heinzel-Wieland Department of Chemical Engineering and Biotechnology, Hochschule Darmstadt, University of Applied Sciences, Stephanstrasse 7, 64295 Darmstadt, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-6151-1638631 Received: 18 December 2017; Accepted: 9 January 2018; Published: 11 January 2018 Abstract: Profound screening and evaluation methods for biocide-releasing polymer films are crucial for predicting applicability and therapeutic outcome of these drug delivery systems. For this purpose, we developed an agar overlay assay embedding biopolymer composite films in a seeded microbial lawn. By combining this approach with model-dependent analysis for agar diffusion, antimicrobial potency of the entrapped drug can be calculated in terms of minimum inhibitory concentrations (MICs). Thus, the topical antiseptic 4-hexylresorcinol (4-HR) was incorporated into poly(lactic-co-glycolic acid) (PLGA) films at different loadings up to 3.7 mg/cm2 surface area through a solvent casting technique. The antimicrobial activity of 4-HR released from these composite films was assessed against a panel of Gram-negative and Gram–positive bacteria, yeasts and filamentous fungi by the proposed assay. All the microbial strains tested were susceptible to PLGA-4-HR films with MIC values down to 0.4% (w/w). The presented approach serves as a reliable method in screening and quantifying the antimicrobial activity of polymer composite films. Moreover, 4-HR-loaded PLGA films are a promising biomaterial that may find future application in the biomedical and packaging sector.
    [Show full text]
  • Mineral Makeup and Its Role with Acne and Rosacea Jane Iredale, MA; Jennifer Linder, MD
    REVIEW Mineral Makeup and Its Role With Acne and Rosacea Jane Iredale, MA; Jennifer Linder, MD Rosacea and acne have been the cause of physical and emotional distress for patients worldwide. Part of the distress has originated from the inability to find products that provide coverage without exacerbating the conditions. This includes understanding the role of certain ingredients with their attendant negative and positive effects. Fifteen years of experience has shown that mineral makeup can play a large part in helping to repair patients’ self-esteem as well as playing a meaningful role in skin improvement. IDENTIFYING AUTHENTIC For physicians to assess mineral makeup and its ben- MINERAL MAKEUP efits for their patients with rosacea and acne, it is neces- Patients with acne and rosacea frequently seek options to sary to explore the chemical composition of authentic cover what they consider toCOS be visually frustrating condi- DERMmineral powder. Many makeup brands are now mar- tions. Regrettably, they often make choices that are not keting products they call mineral makeup, but they effective and potentially detrimental to their situation. do not utilize authentic minerals in their formulations. To serve these patients better, physicians should educate The incorrect use of the word mineral as a marketing themselves and their staffs about camouflaging options. term confuses patients and can lead to the use of prod- Mineral makeup can beDo a satisfactory solutionNot as it is a ucts Copythat can potentially worsen their condition due to healthy, skin-friendly alternative to traditional makeup. problematic ingredients. Mineral makeup not only provides superior coverage and The original definition of mineral makeup is a makeup is easy to use, but it is also UV protective, noncomedo- that eliminates talc, potential skin irritants, and comedo- genic, and anti-inflammatory.
    [Show full text]
  • AP76: 4-Hexyl-Resorcinol CAS#: 136-77-6
    the art and science of smart patch testingTM AP76: 4-hexyl-resorcinol CAS#: 136-77-6 Patient Information Your patch test result indicates that you have a contact allergy to 4-hexyl- resorcinol. This contact allergy may cause your skin to react when it is exposed to this substance although it may take several days for the symptoms to appear. Typical symptoms include redness, swelling, itching, and fluid-filled blisters. Where is 4-hexyl-resorcinol found? 4-hexyl-resorcinol has a long history of human pharmaceutical use as a topical skin and mucosal disinfectant for treatment of superficial wounds, and as a component of soaps, handwashes, and skin cleaners. 4-hexyl-resorcinol has been used in dilute solutions as antiseptic gargles or throat spray, and in lozenges. 4-hexyl-resorcinol is still marketed today as an ingredient of certain throat lozenges. How can you avoid contact with 4-hexyl-resorcinol? Avoid products that list any of the following names in the ingredients: 1,3-Benzenediol, 4-hexyl- Cystoids anthelmintic 1,3-Dihydroxy-4-hexylbenzene EINECS 205-257-4 1,3-Dihydroxy-4-n-hexylbenzene Gelovermin 4-(1-Hexyl)resorcinol Hexylresorcin [German] 4-06-00-06048 (Beilstein Handbook Ref) Hexylresorcinol 4-Hexyl-1,3-benzenediol Hexylresorcinolum 4-Hexyl-1,3-dihydroxybenzene Hexylresorzin 4-Hexylresorcine Hidesol 4-n-Hexylresorcinol HSDB 566 Adrover NCI-C55787 AI3-08055 NSC 1570 Antascarin Oxana Ascaricid p-Hexylresorcinol Ascarinol Prensol Ascaryl Resorcinol, 4-hexyl- BRN 2048312 S.T. 37 Caprokol ST 37 CCRIS 888 ST-37 Crystoids Worm-agen What are some products that may contain 4-hexyl-resorcinol? Cosmetics: Clearasil Adult Care Lotions and Skin Care: KOPNOL Mouthwash / Gargle Throat Lozenges: Sucrets Throat Spray *For additional information about products that might contain 4-hexyl-resorcinol, go to the Household Product Database online (http:/householdproducts.nlm.nih.gov) at the United States National Library of Medicine.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,994,330 El Khoury (45) Date of Patent: Nov.30, 1999
    USOO599433OA United States Patent (19) 11 Patent Number: 5,994,330 El Khoury (45) Date of Patent: Nov.30, 1999 54 TOPICAL APPLICATION OF MUSCARINIC S. Abram, MD et al., Anesth Analg., “Intrathecal Acetyl AGENTS SUCH AS NEOSTIGMNE FOR Cholinesterase Inhibitors Produce Analgesia That is Syner TREATMENT OF ACNE AND OTHER gistic with Morphine and Clonidine in Rats, 81:501-7 NFLAMMATORY CONDITIONS (1995). C. Stein, M.D. et al., New England Journal of Medicine, vol. 76 Inventor: Georges F. El Khoury, 1561 Ramillo 325, No. 16 “Analgesic Effect of Intraarticular Morphine Ave., Long Beach, Calif. 90815 After Arthroscopic Knee Surgery, pp. 1123-1126. T. Yaksh, Ph.D. et al., Anesthesiology, “Studies on the Safety 21 Appl. No.: 09/188,328 of Chronically Administered Intrathecal Neostigmine Meth 22 Filed: Nov. 9, 1998 ylsulfate in Rats and Dogs,” V 82. No. 2, Feb. 1995. “Morphine-A Local Analgesic, International ASSocia (51) Int. Cl." ..................................................... A01N 57/00 tion for the Study of Pain, vol. III. 52 U.S. Cl. .......................... 514/123; 514/123; 514/859; G. Lauretti, MD et al., Anesth Analg “The Effects of 514/855; 514/289; 514/912; 514/78.04; Intrathecal Neostigmine on Somatic and Visceral Pain: 424/401 Improvement by Associate with a Peripheral Anticholin 58 Field of Search ........................... 424/401; 536/55.1; ergic,” 81:615–20 (1996). 514/912, 78.04, 289, 859, 123,855 D. Hood, M.D., et al., Anesthesiology, “Phase I Safety Assessment of Intrathecal Neostigmine Methylsulfate in 56) References Cited Humans,” V 82, No. 2, Feb. 1995 pp. 331-342. U.S.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Canadian Clinical Practice Guideline on the Management of Acne (Full Guideline)
    Appendix 4 (as supplied by the authors): Canadian Clinical Practice Guideline on the Management of Acne (full guideline) Asai, Y 1, Baibergenova A 2, Dutil M 3, Humphrey S 4, Hull P 5, Lynde C 6, Poulin Y 7, Shear N 8, Tan J 9, Toole J 10, Zip C 11 1. Assistant Professor, Queens University, Kingston, Ontario 2. Private practice, Markham, Ontario 3. Assistant Professor, University of Toronto, Toronto, Ontario 4. Clinical Assistant Professor, University of British Columbia, Vancouver, British Columbia 5. Professor, Dalhousie University, Halifax, Nova Scotia 6. Associate Professor, University of Toronto, Toronto, Ontario 7. Associate Clinical Professor, Laval University, Laval, Quebec 8. Professor, University of Toronto, Toronto, Ontario 9. Adjunct Professor, University of Western Ontario, Windsor, Ontario 10. Professor, University of Manitoba, Winnipeg, Manitoba 11. Clinical Associate Professor, University of Calgary, Calgary, Alberta Appendix to: Asai Y, Baibergenova A, Dutil M, et al. Management of acne: Canadian clinical practice guideline. CMAJ 2015. DOI:10.1503/cmaj.140665. Copyright © 2016 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at [email protected]. Contents List of Tables and Figures ............................................................................................................. v I. Introduction ................................................................................................................................ 1 I.1 Is a Clinical Practice Guideline
    [Show full text]